Efficacy of Antibiotic Combinations against Multidrug-Resistant Pseudomonas aeruginosa in Automated Time-Lapse Microscopy and Static Time-Kill Experiments
Open Access
- 21 May 2020
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 64 (6)
- https://doi.org/10.1128/aac.02111-19
Abstract
Objectives: Antibiotic combination therapy is used for severe infections caused by multidrug-resistant (MDR) Gram-negative bacteria. Yet, data of which combinations are most effective is lacking. This study aimed to evaluate the in vitro efficacy of polymyxin B in combination with 13 other antibiotics against four clinical strains of MDR Pseudomonas aeruginosa. Methods: We evaluated the interactions of polymyxin B in combination with amikacin, aztreonam, cefepime, chloramphenicol, ciprofloxacin, fosfomycin, meropenem, minocycline, rifampicin, temocillin, thiamphenicol or trimethoprim by automated time-lapse microscopy using predefined cut-off values indicating inhibition of growth (≤106 CFU/mL) at 24 h. Promising combinations were subsequently evaluated in static time-kill experiments. Results: All strains were intermediate or resistant to polymyxin B, anti-pseudomonal β-lactams, ciprofloxacin and amikacin. Genes encoding β-lactamases (e.g., blaPAO and blaOXA-50) and mutations associated with permeability and efflux were detected in all strains. In the time-lapse microscopy experiments, positive interactions were found with 39 of 52 antibiotic combination/bacterial strain setups. Enhanced activity was found against all four strains with polymyxin B used in combination with aztreonam, cefepime, fosfomycin, minocycline, thiamphenicol and trimethoprim. Time kill experiments showed additive or synergistic activity with 27 of the 39 tested polymyxin B combinations, most frequently with aztreonam, cefepime, and meropenem. Conclusion: Positive interactions were frequently found with the tested combinations, also against strains that harboured several resistance mechanisms to the single drugs and with antibiotics that are normally not active against P. aeruginosa. Further study is needed to explore the clinical utility of these combinations.Funding Information
- Joint Programming Initiative on Antimicrobial Resistance (2015-06825)
- Joint Programming Initiative on Antimicrobial Resistance (2015-06826)
- Swedish Research Council (2019-05911)
This publication has 33 references indexed in Scilit:
- Widespread Fosfomycin Resistance in Gram-Negative Bacteria Attributable to the Chromosomal fosA GenemBio, 2017
- Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B?Antimicrobial Agents and Chemotherapy, 2017
- Synergistic combinations of polymyxinsInternational Journal of Antimicrobial Agents, 2016
- Polymyxin B in Combination with Antimicrobials Lacking In Vitro Activity versus Polymyxin B in Monotherapy in Critically Ill Patients with Acinetobacter baumannii or Pseudomonas aeruginosa InfectionsAntimicrobial Agents and Chemotherapy, 2015
- Assessment of Minocycline and Polymyxin B Combination against Acinetobacter baumanniiAntimicrobial Agents and Chemotherapy, 2015
- Colistin in multi-drug resistant Pseudomonas aeruginosa blood-stream infectionsJournal of Infection, 2014
- Diversity, Epidemiology, and Genetics of Class D β-LactamasesAntimicrobial Agents and Chemotherapy, 2010
- Structure−Activity Relationships of Polymyxin AntibioticsJournal of Medicinal Chemistry, 2009
- Interplay of Efflux System, ampC , and oprD Expression in Carbapenem Resistance of Pseudomonas aeruginosa Clinical IsolatesAntimicrobial Agents and Chemotherapy, 2006
- Substrate Specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM Efflux Pumps in Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2000